Is CTI BioPharma Corp. (CTIC) a Buy, Sell, or Hold?
NASDAQ : CTIC
CTI BioPharma Corp.
$9.095 USD
$0.01 (0.06%)
- Volume
- 5.56M
- Average Volume
- 6.36M
- Market Capitalization
- $1.2B
- P/E Ratio
- -11.51
- Dividend Yield
- 0.00%
- Price Target
- $9.00
- Year High
- $9.10
- Year Low
- $4.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.23
Company Overview
NASDAQ
Adam R. Craig
Biotechnology
Healthcare
CTIC
127
US
USD
Liquidity Metrics
-2.84
1.23
1.22
0.37
0.00
Sales & Valuation
$53.95M
22.23
-59.35
-11.29
-0.93
Profitability
-$0.79
-$91.04M
-168.76%
-172.37%
1318.48%
-72.30%
P/E Metrics
-11.51
-0.17
-0.17
Analyst Price Target & Rating
$9.00
$13.00
$9.00
0/5
19 Analysts
1.06%
Financial Health Scores
-27.07
3/9
$18.23M
$112.27M
$137.62M
-$54.04M
Key Metrics (TTM)
$1.22B
22.60
-15.65
1.23
1318.48%
-84.24%
-8.73%
-8.85%
-28 days
Company Executives
| Name | Title |
|---|---|
| Adam R. Craig | Pres, Chief Executive Officer, Interim Chief Medical Officer & Director |
| John Volpone | Executive Vice President & Chief of Staff |
| James K. Fong | Executive Vice President & Chief Commercial Officer |
| Bruce K. Bennett Jr. | Senior Vice President Global Pharmaceutical Operations |
| Jennifer A. Smith | Senior Vice President of Biometrics |
| David H. Kirske | Executive Vice President, Chief Financial Officer & Sec. |
| Ed Bell | Senior Director of Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About CTI BioPharma Corp. (NASDAQ:CTIC) Stock
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014. ...
Frequently Asked Questions
-
What is the current CTI BioPharma Corp. (CTIC) stock price?
-
CTI BioPharma Corp.(NASDAQ:CTIC) stock price is $9.095 in the last trading session. During the trading session, CTIC stock reached the peak price of $9.1 while $4.01 was the lowest point it dropped to. The percentage change in CTIC stock occurred in the recent session was 0.06% while the dollar amount for the price change in CTIC stock was $0.01.
-
CTIC's industry and sector of operation?
-
The NASDAQ listed CTIC is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CTIC?
-
Adam R. Craig | Pres, Chief Executive Officer, Interim Chief Medical Officer & Director
John Volpone | Executive Vice President & Chief of Staff
James K. Fong | Executive Vice President & Chief Commercial Officer
Bruce K. Bennett Jr. | Senior Vice President Global Pharmaceutical Operations
Jennifer A. Smith | Senior Vice President of Biometrics -
How many employees does CTIC have?
-
Number of CTIC employees currently stands at 127. CTIC operates from 3101 Western Avenue, Seattle, WA 98121, US.
-
Link for CTIC official website?
-
Official Website of CTIC is: https://www.ctibiopharma.com
-
How do I contact CTIC?
-
CTIC could be contacted at phone #206 282 7100 and can also be accessed through its website. CTIC operates from 3101 Western Avenue, Seattle, WA 98121, US.
-
How many shares of CTIC are traded daily?
-
The average number of CTIC shares traded daily for last 3 months was 6.36M.
-
What is the market cap of CTIC currently?
-
The market value of CTIC currently stands at $1.2B with its latest stock price at $9.095